Sanofi SNY and partner Regeneron REGN announced that the European Medicines Agency’s Committee for Medicinal Products for ...

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to ...

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and ...

DelveInsight's Interleukin-13 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of best affordable biotech stocks to invest in now. Regeneron ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

RBC Capital Markets launched its coverage of Kymera Therapeutics (NASDAQ:KYMR) with an Outperform rating on Tuesday, citing the potential of its lead drug KT-621, targeted at inflammatory conditions ...

These readouts will help Regeneron structure the confirmatory trials for the two allergy combination therapies.

Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone ...

REGN1908 and REGN1909 are two fully human monoclonal antibodies (mAbs) targeting and blocking FelD1. In the Phase 3 trial, cat-allergic participants were randomized to receive a single dose of the ...

TARRYTOWN, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results evaluating its first-in-class investigational allergen-blocking antibodies in ...

Regeneron’s allergen-blocking antibodies have reduced the symptoms of cat and pollen allergies in a pair of phase 3 studies. One of these studies saw 64 patients with cat allergy receive either ...